Serina Therapeutics (SER) Convertible Debt (2023 - 2026)

Serina Therapeutics has disclosed Convertible Debt across 3 years of filings, most recently posting $3.1 million for Q2 2026.

• In Q2 2026, Convertible Debt changed N/A year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $3.1 million (changed N/A YoY), while the FY2025 annual figure was $2.9 million, changed N/A from the prior year.
• Convertible Debt came in at $3.1 million for Q2 2026 at Serina Therapeutics, up from $2.9 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $3.1 million in Q2 2026 to a low of $2.9 million in Q4 2025.
• Average Convertible Debt over 3 years is $3.0 million, with a median of $3.0 million recorded in 2023.